ANIP vs ASTH: fair value comparison
ANI Pharmaceuticals, Inc. and Astrana Health, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ASTH currently sits closer to the top of our discount ranking. ANIP carries the stronger quality grade.
| ANIP | ASTH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $80.06 | $35.91 |
| 12-month range | $75.22–$94.10 | $22.32–$49.81 |
| Sector rank | #11 of 113 Healthcare | #7 of 113 Healthcare |
| Quality grade | C- | D |
| Momentum grade | B | — |
| Leverage | Moderate | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: ANIP fair value analysis · ASTH fair value analysis